The largest database of trusted experimental protocols
> Anatomy > Body Substance > Calculi, Biliary

Calculi, Biliary

Calculi, Biliary are solid concretions that form within the biliary tract, usually in the gallbladder or common bile duct.
These stones can vary in size, composition, and clinical significance.
Biliary calculi can cause obstruction, inflammation, and other serious complications if left untreated.
Researchers and clinicians can leverage PubCompare.ai's AI-driven comparison platform to efficientlly locate relevant protocols from literature, preprints, and patents, and utilize intelligent comparison tools to identify the best protocols and products for managing biliary calculi.
This streamlines the research process and supports informed decision-making.

Most cited protocols related to «Calculi, Biliary»

Indication for prescription was not available on pharmacy records. At Group Health in 2001–2003 we determined indication through ICD-9 codes recorded on visit encounters to the prescribing physician that occurred within 90 days of the initial prescription (N=151,314 episodes of opioid use). It was possible to link a preceding encounter within 90 days to an initial opioid prescription for 74.4% of the episodes. The most common diagnostic groups observed on the linked encounters were: extremity pain (13.4%); back pain (13.3%); fractures, contusions, injury (7.1%); abdominal pain/hernia (5.1%); osteoarthritis (3.8%); neck pain (3.6 %); headache (2.6 %); kidney stones/gall stones (1.9%); and menstrual/reproductive pain (1.0%).
Publication 2008
Abdominal Pain Back Pain Calculi, Biliary Contusions Degenerative Arthritides Diagnosis Dysmenorrhea Fracture, Bone Headache Hernia Hernia, Abdominal Injuries Kidney Calculi Neck Pain Opioids Pain Physicians Reproduction
Details of the study have been reported elsewhere (3 (link), 5 –7 (link),10 (link)–12 (link)). Briefly, primary biliary tract cancer cases (ICD-9 156) diagnosed between 1997 and 2000 were identified through a rapid-reporting system established by the Shanghai Cancer Institute (SCI) with 42 collaborating hospitals in urban Shanghai. This system captured more than 95% of all biliary tract cancers diagnosed in Shanghai. Case patients were permanent residents of urban Shanghai between 40 to 75 years of age. A total of 411 patients with biliary tract cancer (237 gallbladder, 127 bile duct, and 47 ampulla of Vater) were included. In addition, we selected a total of 1,037 biliary stone cases (774 gallstone and 263 bile duct stone patients) from the same hospitals from which the cancer cases were selected. Biliary stone cases had no history of cancer and were matched to index cancer cases on gender, age (within 5 years), and hospital. A total of 959 healthy subjects who were randomly selected from the urban Shanghai population (6.5 million permanent residents), using the Shanghai Resident Registry records, were included in this study as population controls. Controls were free of non-skin cancer and were frequency-matched to cancer cases in a 1-to-1 ratio by age (within 5 years) and gender distributions. All study subjects provided written informed consent. The Institutional Review Boards of the National Cancer Institute and SCI approved the study protocol.
Publication 2008
Ampulla of Vater Biliary Tract Cancer Calculi Calculi, Biliary Cancer of Skin Cholelithiasis Duct, Bile Ethics Committees, Research Gallbladder Healthy Volunteers Malignant Neoplasms Patients Urban Population
A total of 3305 patients underwent ERCP in our hospital between October 2009 and September 2014 and 258 were diagnosed with difficult biliary cannulation. Of these 258 patients, 58 of them had their index ERCP with successful cannulations and underwent subsequent limited PS combined with EPBD for CBD stone removal. These 58 patients were analyzed in this retrospective study. On the other hand, two hundred of these patients encountered a first unsuccessful ERCP due to difficult biliary cannulation and then decided not to have a second one (none of them had received limited precut procedure). One hundred and fifty-five of them chose to receive surgery; 42 of them were treated by percutaneous biliary drainage and 3 received supportive treatments.
The definition of difficult biliary cannulation in our study was as follows: (1) failed cannulation within 10 min (2) 5 passages or injections of the pancreatic duct, or (3) 10 attempts at the papilla without a time limit (Fig. 1a). We stopped anticoagulant administration such as aspirin for 7 days before the procedures in those who were prescribed for primary prevention. For those who received anticoagulant for secondary prevention in low cardiovascular risk patients, we stopped clopidogrel, prasugrel, ticagrelor and coumadin 5 days before ERCP according to British Society of Gastroenterology and European Society of Gastrointestinal endoscopy [14 (link), 15 (link)]. For patients with high cardiovascular risks, the procedures were postponed if possible until anticoagulant could be discontinued safely (usually >12 months after insertion of drug-eluting coronary stents or >1 month after insertion of bare metal coronary stents). However, when an emergent or semi-emergent indication like an impacted stone or jaundice in need of immediate action was encountered, cardiologists were routinely consulted and replaced by other emergent non-endoscopic bilary driange procedures. Prophylactic NSAIDs were given to all patients to reduce risk of post-ERCP pancreatitis routinely in our department.

a Difficult biliary cannulation was due to failure of 10 attempts at duodenal papilla; (b) Limited precut sphincterotomy was performed with the extent of cutting was less than half the length of the papillary mound; (c) Common bile duct stone was found after successful biliary cannulation; (d) Endoscopic papillary balloon dilation was performed after limited precut sphincterotomy; (e and f) Common bile duct stone was extracted by retrieval balloon

The patients received pharyngeal anesthesia with xylocaine spray in the same manner as that for general endoscopy. Hyoscine-N-butylbromide (20 mg) was administered intramuscularly before the procedure, and meperidine (30 to 50 mg) was administered before EPBD. ERCP was performed using a side-view endoscope (JF 260v and TJF 240; Olympus, Tokyo, Japan) after selective cannulation of the CBD with a cholangiography catheter (PR-113Q, Olympus). We preferred a needle-knife sphincterotome (KD-V441, Olympus) in all cases. Two highly experienced endoscopists [the first and second authors], with experiences of more than 3000 ERCPs procedures each, and ongoing workloads of more than 250 ERCPs procedures each annually, performed all the limited PS combined with EPBD procedures. Diathermy was applied with a blended current (20 W cut and 20 W coagulation) using the ESG 100 system (Olympus). The incision started from the lip of the papillary orifice (at the 11-o’clock position) and proceeded upward over the papillary mound. The extent of cutting in limited PS is less than half the length of the papillary mound (Fig. 1b). To perform EPBD after cannulation of the bile duct with limited PS (Fig. 1c), a 0.035-inch guide-wire (Zebra Exchange Guide-wire; Microvasive Boston Scientific, Watertown, MA) was inserted into the bile duct through the catheter. After the guide-wire was inserted deeply into the bile duct, the catheter was removed with the guide-wire left in place. A balloon-tipped catheter (5.5 cm long and 8–20 mm wide; Microvasive Boston Scientific), was inserted over the guide-wire so that the balloon was extended across the papilla. The balloon was inflated to 8–20 mm in diameter with saline solution to dilate the papilla at progressively increasing pressures of 3 to 8 atm for 2 min, according to the size of the CBD stones (Fig. 1d). After removing the dilation catheter, stones were extracted with a basket catheter or retrieval balloon (Fig. 1e, f). Endoscopic mechanical lithotripsy (EML) was used to crush stones >15 mm in diameter when extraction of these stones was difficult after EPBD. When stones were not extracted completely, a biliary stent was inserted and the residual stones were removed after 3–7 days without repeating EPBD. A prophylactic pancreatic stent was not used after EPBD. Complete stone removal was defined as the absence of bile duct stones on a balloon occlusion cholangiogram.
Publication 2016
Anesthesia Anti-Inflammatory Agents, Non-Steroidal Anticoagulants Aspirin Balloon Occlusion Bile Butylscopolammonium Bromide Calculi Calculi, Biliary Cannulation Cardiologists Catheters Cholangiography Clopidogrel Coagulation, Blood Common Bile Duct Calculi Condoms Coumadin Diathermy Dilatation Drainage Drug-Eluting Stents Duct, Bile Duodenum Endoscopes Endoscopic Retrograde Cholangiopancreatography Endoscopy Endoscopy, Gastrointestinal Europeans Heart Icterus Lithotripsy Meperidine Metals Needles Nipples Operative Surgical Procedures Pancreas Pancreatic Duct Pancreatitis Patients Pharynx Prasugrel Primary Prevention Saline Solution Secondary Prevention Sphincterotomy Stents Surgical Endoscopy Ticagrelor Xylocaine Zebras
This association study was designed as a retrospective study, including 657 patients with chronic HBV infection (CHB) and 299 healthy controls. All subjects were ethnic Han Chinese. CHB patients recruited between 2012 and 2015 at The First Hospital of Jilin University (Changchun) were further classified into non-HCC (n = 370) and HBV-related HCC (n = 287) patients. Frequency matching by age and sex was performed for each group. CHB patients were defined by persistent or intermittent elevations in alanine transaminase level (≥ 2 times the upper limit of normal) and elevated HBV DNA levels for at least 6 mo. HBV-related HCC was diagnosed based on (1) positive results on computed tomography (CT), magnetic resonance imaging or ultrasonography; and (2) combined positive findings upon cytological or pathological examination. The non-HCC patients included CHB and LC patients, characterized by active necro-inflammatory liver disease without/with fibrosis on imaging examination without evidence of HCC, according to the guidelines for the prevention and treatment of CHB (2010 version), and the diagnostic criteria (10th National Conference on Viral Hepatitis and Hepatopathy 2000, China). All samples were HBV-positive, but hepatitis C virus (HCV)-, HIV-negative, according to serology tests and infection history. Exclusion criteria included the presence of autoimmune and other liver diseases, alcoholic liver disease, hemorrhagic liver disease, and intra- and extra-hepatic bile duct stones. The criteria for healthy participants included no previous diagnosis of cancer or liver-associated illness. Healthy individuals were recruited from The First Hospital of Jilin University during the same period. All patients were further confirmed as being negative for hepatitis B surface antigen, hepatitis B e antigen (HBeAg), hepatitis B e antibody (HBeAb), hepatitis B virus core antibody, and hepatitis C antibody, as measured by chemiluminescence methods (Roche E411, Basil, Switzerland). We also collected demographic data of each subject, such as smoking and drinking status. Individuals who smoked daily for at least 1 year were defined as smokers, and those who consumed alcoholic drinks more than once per wk for over 6 mo were considered drinkers. Written informed consent was obtained from all patients, and this study was approved by The First Hospital Ethical Committee of Jilin University.
Publication 2017
Alanine Transaminase Alcoholic Beverages Alcoholic Liver Diseases Calculi, Biliary Chemiluminescence Chinese Chronic Infection Conferences Diagnosis Fibrosis Healthy Volunteers Hemorrhagic Disorders Hepatitis Hepatitis B Antibodies Hepatitis B e Antigens Hepatitis B Surface Antigens Hepatitis C Antibodies Hepatitis C virus Hepatitis Viruses Infection Liver Liver Diseases Malignant Neoplasms Ocimum basilicum Patients Tests, Serologic Ultrasonography X-Ray Computed Tomography
Two control groups were used in the present study: i) a lean control group (LC, BMI ℋ 25 kg/m2) and ii) an obese control group (OC, BMI > 30 kg/m2). Both control groups did not receive any intervention, and therefore their body weight maintained stable throughout the study period of 6 months. Each group included 13 subjects (2 men, 11 women). Inclusion criteria were: between 20 and 66 years of age, Caucasian descent, and BMI ℋ 25 kg/m2 (LC) or BMI > 30 kg/m2 (OC). The baseline characteristics of the control groups are shown in table 1. The controls were embedded in the ‘Kiel intervention cohort’ as part of the ‘Food Chain Plus’ study [17 (link)]. A written informed consent was obtained from each subject before they were included into this study. 11 of the 26 subjects suffered from hypertension, and 7 showed high blood lipids. Two subjects each had diabetes mellitus, liver disease, migraine, acne, psoriasis, neurodermatitis, and gall stones. One each had cardiac insufficiency, multiple sclerosis, and urticaria. In the past, 3 subjects had cancer and biliary operations, and 2 had venous thrombosis. In terms of pharmacotherapy, 7 patients were taking beta blockers, and 6 subjects were taking thyroxine. Five subjects each were on ACE inhibitors and proton pump inhibitors. Three each were taking statins and glucocorticoids. Two were on diabetic therapy, 1 was taking metformin, and 1 was on insulin therapy. Four were taking antidepressant agents, and 5 were taking diuretics. One each was taking sedatives, uricostatics, chelating agents, calcium antagonists, anticholinergic agents, symphatomimetic drugs, antihistamines, uricosuric agents, and fibrates. Four subjects each were taking vitamin or mineral supplements and angiotensin II receptor antagonists. Two each were on pain killers and anticoagulants. Subjects were advised not to change the dosage throughout the study period to achieve stable conditions.
Publication 2016
Acne Vulgaris Adrenergic beta-Antagonists Analgesics Angiotensin-Converting Enzyme Inhibitors Angiotensin II Type 2 Receptor Blockers Anticholinergic Agents Anticoagulants Antidepressive Agents Biliary Tract Surgical Procedures BLOOD Body Weight Calcium Channel Blockers Calculi, Biliary Chelating Agents Diabetes Mellitus Dietary Supplements Diuretics Fibrates Food Chain Glucocorticoids Heart Failure High Blood Pressures Histamine Antagonists Hydroxymethylglutaryl-CoA Reductase Inhibitors Insulin Lipids Liver Diseases Malignant Neoplasms Metformin Migraine Disorders Minerals Multiple Sclerosis Neurodermatitis Obesity Patients Pharmaceutical Preparations Pharmacotherapy Proton Pump Inhibitors Psoriasis Sedatives Therapeutics Thyroxine Uricosuric Agents Urticaria Venous Thrombosis Vitamins White Person Woman

Most recents protocols related to «Calculi, Biliary»

21. Irritable bowel syndrome
22. Inflammatory bowel disease
23. Coeliac disease
24. Chronic liver disease
25. Peptic ulcer
26. Gall stones
Publication 2023
Calculi, Biliary Digestion Inflammation Intestines Irritable Bowel Syndrome Liver
All consecutive patients aged 18 years or older with a confirmed diagnosis of HT after AIS between January 2012 and June 2022 were enrolled in this retrospective cohort study conducted at the Stroke Center of the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
This study was approved by the Institutional Review Board and Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University. The requirement for informed consent was waived as this was a retrospective study and all data were anonymous.
The diagnosis of first-ever AIS was confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) at admission. The exclusion criteria were: a diagnosis of hemorrhagic stroke or transient ischemic attacks; a previous history of biliary calculus, cholecystitis, or malignancy; serum transaminase concentration greater than twice the upper limit of the reference range within 6 months; hepatitis B or C virus positivity; chronic kidney disease (glomerular filtration rate < 60 mL min−1 1.73 m−2); ongoing infection or inflammation; alcoholism (consumption of at least 40 g alcohol/day for males and ≥ 20 g/day for females during the previous 3 months); having received intravenous thrombolytic therapy; failure to undergo a second CT/MRI scan; and incomplete medical records.
A final total of 408 consecutive patients diagnosed with HT after AIS, consisting of 247 with sHT and 161 with HT after thrombectomy (tHT), were included in this study. The same number of age- and sex-matched AIS inpatients without HT for each cohort were randomly selected from the Stroke Center of our institution between January 2017 and June 2022 as controls. All patients met the inclusion criteria.
Publication 2023
Alcoholic Intoxication, Chronic Calculi, Biliary Cerebrovascular Accident Cholecystitis Chronic Kidney Diseases Ethics Committees, Clinical Ethics Committees, Research Females Glomerular Filtration Rate Hemorrhagic Stroke Hepatitis B Infection Inflammation Inpatient Magnetic Resonance Imaging Males Malignant Neoplasms Patients Serum Thrombectomy Thrombolytic Therapy Transaminases Transient Ischemic Attack Virus X-Ray Computed Tomography
All CT scans were performed using the picture archiving and communication system (PACS; Pathspeed, Pathspeed, GE Medical Systems Integrated Imaging Solutions) and were independently evaluated by two radiologists imaging features. The two radiologists did not know the clinical indicators or pathological findings. A consensus was reached by joint discussion when there was disagreement between the two physicians. The main observations were the maximum length of the lesion; its location (divided into base, base + body, body, body + neck, and neck); the number of the lesion (single or multiple); the base status (the base width of GPs was as about Yamada’s classification: the angle between the protuberance of the GPs and the basement mucosa > 90° is referred to as the wide base, whereas the angle < 90°is defined narrow base [11 (link)]); gallbladder stones (absent or present); and lesions CT values in the plain and triphasic dynamic enhanced scan.
Publication 2023
Atrial Premature Complexes Basal Bodies Calculi, Biliary Human Body Joints Mucous Membrane Neck Physicians Radiologist Radionuclide Imaging X-Ray Computed Tomography
The present study was approved by the Medical Ethics Committee of the Affiliated Hospital of North Sichuan Medical College and was exempted from informed consent requirements owing to its retrospective design (2020ER203-1). All the procedures performed in this study were in accordance with the Declaration of Helsinki (as revised in 2013).
The medical records of patients with AP treated at our hospital from January 2017 to December 2020 were consecutively reviewed, and follow up occurred through telephone or admission notes to record recurrence. In line with the inclusion and exclusion criteria, 212 patients were excluded and a total of 201 patients were recruited (Fig. 1). Based on the recurrence results during the follow-up period, the cases were split into a nonrecurrence group (n = 102) and a recurrence group (n = 99). The average time interval between the first attack and the second attack in the recurrence group was 21.9 ± 14.7 months. Using computer-generated random numbers in R software, the datasets were randomly split in a 7:3 ratio into a training cohort (n = 140, 71 in the nonrecurrence group, 69 in the recurrence group) and a testing cohort (n = 61, 31 in the nonrecurrence group, 30 in the recurrence group). Furthermore, class-relevant clinical characteristics of the patients were collected, including age and sex; history of alcoholism, smoking or hyperlipidemia; and disease characteristics such as severity, the MR severity index (MRSI) score, biochemical indices of pancreatitis (serum amylase, lipase, and pancreatic amylase levels), and the presence of biliary stones or local complications.

Flowchart of subject recruitment in this study. AP, acute pancreatitis; CE-MRI, contrast-enhanced MRI; CP, chronic pancreatitis.

Publication 2023
Alcoholic Intoxication, Chronic alpha-Amylases Amylase Calculi, Biliary Ethics Committees, Clinical Hereditary pancreatitis Hyperlipidemia Lipase Pancreatitis Pancreatitis, Acute Patients Recurrence Serum
This was a single-center study conducted at the Institute of Liver and Biliary Sciences (ILBS), New Delhi, India. We retrospectively analyzed patients with EHPVO and PCC who were evaluated between Jan 2012 and Dec 2019. A CT angiography was the study of choice for characterizing extra hepatic portal vein anomalies. ERCP and magnetic resonance cholangiography were used in the evaluation of biliary tract anomalies. A dynamic triple-phase multi-dissection computerized tomography (MDCT) study was performed on a 64-row spectral CT scanner. MRCP imaging was performed on a 3 Tesla scanner using a phased array TORSOPA coil. Sixty cases with clinically and radiologically proven portal cavernoma cholangiography who had complete clinical details recorded in 8 years (January 2012–December 2019) were found.
The inclusion criterion consisted of patients with EHPVO with overlying features of PCC. The triad used to make a diagnosis is the presence of portal cavernoma cholangiography changes on ERCP or MRCP, and the absence of alternate etiologies of biliary duct changes. An adequate liver biopsy i.e., at least 1.5 cm, and the presence of at least 10 complete portal tracts were considered. Patients with other etiologies of portal vein thrombosis or biliopathy such as hepatic and pancreatic malignancies, chronic liver disease, sclerosing cholangitis, and biliary calculi were excluded. Ten cases were excluded as per the mentioned exclusion criteria.
The institutional ethics committee of the Institute of Liver and Biliary Sciences, Delhi approved the study (approval code: IEC/2020/82/MA11B on 11th October 2020).
Publication 2023
Bile Biopsy Calculi, Biliary CAT SCANNERS X RAY Cholangiography Computed Tomography Angiography Diagnosis Disease, Chronic Dissection Duct, Bile Endoscopic Retrograde Cholangiopancreatography Hemangioma, Cavernous Hepatobiliary Disorder Institutional Ethics Committees Magnetic Resonance Imaging Pancreatic Carcinoma Patients Portal System Primary Sclerosing Cholangitis System, Biliary Triad resin Veins, Portal Venous Thrombosis X-Ray Computed Tomography

Top products related to «Calculi, Biliary»

Sourced in Germany, United States, France, United Kingdom, Netherlands, Spain, Japan, China, Italy, Canada, Switzerland, Australia, Sweden, India, Belgium, Brazil, Denmark
The QIAamp DNA Mini Kit is a laboratory equipment product designed for the purification of genomic DNA from a variety of sample types. It utilizes a silica-membrane-based technology to efficiently capture and purify DNA, which can then be used for various downstream applications.
Sourced in Japan
Polarizing light microscopy is an optical microscopy technique that uses polarized light to analyze the internal structure and properties of materials. It is designed to provide information about the optical anisotropy, birefringence, and other polarization-dependent characteristics of samples.
The 1100 HPLC is a high-performance liquid chromatography system designed for a wide range of analytical applications. It features precise solvent delivery, reliable autosampling, and sensitive detection capabilities.
Sourced in United States
AKR/J mice are an inbred mouse strain used in research. They are derived from the AK strain originally developed in 1929. AKR/J mice have a high incidence of spontaneous lymphoma, which can be useful for certain types of research.
Sourced in United States, Austria, Japan, Cameroon
SAS statistical software is a comprehensive data analysis and visualization tool. It provides a wide range of statistical procedures and analytical capabilities for managing, analyzing, and presenting data. The software is designed to handle large and complex datasets, allowing users to perform advanced statistical modeling, regression analysis, and data mining tasks. The core function of the SAS statistical software is to enable users to extract insights and make data-driven decisions.
Sourced in United States, United Kingdom
Stata/SE 15.1 is a data analysis and statistical software package developed by StataCorp. It provides a comprehensive set of tools for data management, analysis, and visualization. Stata/SE 15.1 is designed to handle large datasets and perform advanced statistical modeling. The software offers a wide range of features and functionalities to support researchers, analysts, and professionals in various fields.
Sourced in United States
The Launcher is a device designed for use in medical laboratories. It is a compact, mechanical instrument that is used to launch or propel small objects or samples in a controlled and consistent manner. The Launcher's core function is to provide a reliable and precise method for introducing test materials into analytical equipment or processes.
Sourced in United States, China, Japan, Italy, Germany, United Kingdom, Switzerland, France, Canada, Netherlands, Australia, Belgium, India
The Microplate reader is a laboratory instrument used to measure the absorbance or fluorescence of samples in a microplate format. It can be used to conduct various assays, such as enzyme-linked immunosorbent assays (ELISA), cell-based assays, and other biochemical analyses. The core function of the Microplate reader is to precisely quantify the optical properties of the samples in a multi-well microplate.
Sourced in United States, United Kingdom
The Nicolet iN10 is a compact and versatile Fourier Transform Infrared (FTIR) microscope designed for materials analysis. It provides high-quality infrared spectroscopic imaging and data acquisition capabilities for a wide range of sample types and applications.

More about "Calculi, Biliary"

Calculi, Biliary are solid concretions that form within the biliary tract, often in the gallbladder or common bile duct.
These gallstones can vary in size, composition, and clinical significance.
Biliary calculi can cause obstruction, inflammation, and other serious complications if left untreated.
Researchers and clinicians can leverage PubCompare.ai's AI-driven comparison platform to efficiently locate relevant protocols from literature, preprints, and patents, and utilize intelligent comparison tools to identify the best protocols and products for managing biliary calculi.
This streamlines the research process and supports informed decision-making.
Biliary stones, also known as cholelithiasis or gallstones, are a common health issue that affects the biliary system.
They can be composed of cholesterol, bilirubin, or a combination of substances.
Factors that contribute to their formation include diet, obesity, hormonal changes, and underlying medical conditions.
The clinical presentation of biliary calculi can range from asymptomatic to severe, including symptoms like abdominal pain, nausea, vomiting, and jaundice.
Diagnosis often involves imaging techniques such as ultrasound, CT scan, or Polarizing light microscopy.
Management of biliary calculi typically involves conservative treatment, dissolution therapy, or surgical intervention, such as cholecystectomy (gallbladder removal).
The choice of treatment depends on the size, location, and composition of the stones, as well as the patient's overall health and medical history.
Researchers studying biliary calculi may utilize a variety of tools and techniques, including the QIAamp DNA Mini Kit for genetic analysis, 1100 HPLC for stone composition analysis, and SAS or Stata/SE 15.1 statistical software for data analysis.
Animal models like AKR/J mice may also be employed to investigate the underlying mechanisms of stone formation and potential interventions.
By leveraging the AI-driven comparison platform of PubCompare.ai, researchers and clinicians can efficiently navigate the wealth of information available on biliary calculi, from literature and preprints to patents.
This allows for the identification of the most relevant protocols and products, streamlining the research process and supporting informed decision-making in the management of this common and potentially serious condition.